View Future GrowthMolecular Data 過去の業績過去 基準チェック /06Molecular Dataの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Trade Distributors 業界の成長23.44%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Jun 2021最近の業績更新Reported Earnings • Oct 07First half 2021 earnings released: CN¥0.22 loss per shareThe company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020).すべての更新を表示Recent updatesお知らせ • Oct 27Nasdaq Stock Market to Delist the American Depositary Shares of Molecular Data IncOn October 26, 2022, Nasdaq Stock Market announced that it will delist the American Depositary Shares of Molecular Data Inc. Molecular Data’s securities were suspended on September 7, 2022, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting become effective ten days after the Form 25 is filed.Board Change • Aug 02High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 25Molecular Data Receives NASDAQ NotificationMolecular Data Inc. announced that it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that to date, it has not regained compliance with the Rule 5250(c)(1). Since the Company is already before a Hearings Panel for its failure to comply with the $1.00 minimum bid price requirement set forth in Listing Rule 5550(a)(2),pursuant to Listing Rule 5810(d)(2), rather than submit a compliance plan for Staff's review, the Company is to address the matter before the Hearings Panel.お知らせ • May 29Molecular Data Inc. Receives NASDAQ Notification Regarding Minimum Bid RequirementsMolecular Data Inc. announced that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that its minimum closing bid price per share for its ordinary shares had fallen below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On November 29, 2021, the Company was provided with an additional 180 calendar day compliance period, or until May 23, 2022, to demonstrate compliance. On May 24, 2022, the Company received notice from Nasdaq that it has not regained compliance with Listing Rule 5550(a)(2) and that its American Depository Shares ("ADS") would be delisted from the Capital Markets and a Form 25- NSE filed with the Securities and Exchange Commission (the "SEC") to remove the Company's securities from listing and registration on The Nasdaq Stock Market unless the Company requests a hearing for an appeal. On May 26, 2022, the Company submitted a hearing request to a Hearings Panel (the "Panel") for an appeal pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The hearing request will stay the suspension and delisting action pending the issuance of a written Panel decision.お知らせ • May 21Molecular Data Announces Receipt of Nasdaq Non-Compliance LetterOn May 20, 2022, Molecular Data Inc. announced that on May 17, 2022, it received a Delinquency Compliance Plan Alert Letter (the "Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), because it has not timely filed its annual report on Form 20-F for the period ended December 31, 2021. In the Letter, Nasdaq stated that the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Company's Form 20-F's filing due date, or until November 14, 2022, to regain compliance.お知らせ • May 03Molecular Data Inc. announced delayed 20-F filingOn 05/02/2022, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.Board Change • Apr 27High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 08Molecular Data Inc. Adopts Blockchain to Enhance its PlatformMolecular Data Inc. has upgraded its platform using Blockchain for its current chemical business. With properties of Blockchain including traceability and transparency, such an adoption can be applied in numerous processes from the front to back end in the current business to improve credibility. Also, the transactions efficiency and safety will be enhanced.Reported Earnings • Oct 07First half 2021 earnings released: CN¥0.22 loss per shareThe company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020).お知らせ • Sep 24Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million.Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 23,390,000 Price\Range: $0.38 Discount Per Security: $0.0304 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 16,083,684 Price\Range: $0.3799 Discount Per Security: $0.030392 Transaction Features: Registered Direct Offeringお知らせ • Jul 15Molecular Data Inc. announced that it expects to receive $1.9 million in funding from Yorkville Advisors Global LPMolecular Data Inc. announced that it has entered into a securities purchase agreement with returning investor, YA II PN, Ltd., a fund managed by Yorkville Advisors Global LP for a private placement of convertible debentures for gross proceeds of $1,900,000 on July 14, 2021. The convertible debentures bear interest of 5% per year. The securities are issued at a discount of 5%. The investor shall be entitled to convert any portion of the outstanding and unpaid conversion amount into fully paid and nonassessable ordinary Shares. The debenture will mature on July 14, 2022 unless earlier converted or redeemed. Upon conversion, the company will issue American depositary shares to the investor. The initial conversion price shall be the lower of $1.30 per share, or 88% of a reference price benchmarked against trading price of the company's shares. Each American depositary share represents three class A ordinary shares of the company.お知らせ • May 04Molecular Data Inc. announced delayed 20-F filingOn 05/03/2021, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Apr 10Molecular Data Inc. announced that it has received $7.5 million in fundingMolecular Data Inc. (NasdaqCM:MKD) announced that it has raised up to $7.5 million in a round of funding from accredited investor on April 9, 2021.お知らせ • Mar 11Molecular Data Inc. Enters Supply Framework Agreement with Anhui Gujing Distillery Co., LtdMolecular Data Inc. announced that it has entered into a supply framework agreement with Anhui Gujing Distillery Co. Ltd. ("Gujing"), one of the most important core enterprises in China's liquor market, as part of its efforts to expand presence in the food and beverage industry. Under the agreement, Molecular Data will become a key supplier for Gujing and its affiliated companies, including Anhui Runan Xinke Testing Technology Co. Ltd.("Runan Xinke") and Anhui Ruisi Weier Technology Co. Ltd. ("Ruisi Weier"), in the fields of chemical reagents, biological reagents, laboratory consumables, as well as related instruments and equipment. Molecular Data will source nearly 2 million stock-keeping units (SKUs) that Gujing requires from its 21 well-known domestic and foreign laboratory brands and suppliers. Molecular Data'sMKD Lab Supplies Mall is a data-driven one-stop laboratory supplies e-commerce service platform, which covers all categories of chemical reagents, biological reagents, laboratory consumables, and equipment. The mall serves scientific research institutions, hospitals, university laboratories, third-party testing units and production plants, providing procurement services that include all categories of reagents and intermediates. With a history of more than 1,800 years, Gujing Gongjiu is one of the eight most prestigious liquor brands in China, and has won the gold medal in the national spirits appraisal four times consecutively. Gujing's research capabilities in liquor are also industry leading. In accordance with the national standards of top laboratories, Gujing has established research and development centers, national post-doctoral research workstations, academic workstations, national food enterprise quality and safety testing technology demonstration centers and other scientific research platforms. Both affiliates of Gujing, Runan Xinke is a state-owned third-party testing institution that provides one-stop testing services from inspection to testing and technical services with various national certification; while Ruisi Weier has been striving for technology development related to biological fermentation engineering. The collaboration with Gujing is another milestone for Molecular Datato propel digitalization of the traditional industries and empower intelligent manufacturing in China. Molecular Data will continue to optimize supply chain services and upgrade the digital products, helping enterprises both from China and abroad to reduce costs and increase efficiency to spur the development of the industry.Is New 90 Day High Low • Feb 13New 90-day high: US$1.87The company is up 68% from its price of US$1.11 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 10.0% over the same period.分析記事 • Jan 16What Percentage Of Molecular Data Inc. (NASDAQ:MKD) Shares Do Insiders Own?The big shareholder groups in Molecular Data Inc. ( NASDAQ:MKD ) have power over the company. Insiders often own a...Is New 90 Day High Low • Jan 16New 90-day low: US$0.80The company is down 28% from its price of US$1.12 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is flat over the same period.お知らせ • Dec 30Molecular Data Inc. Announces Cessation of Dongliang Chang as Member of the Audit Committee of the Board of DirectorsMolecular Data Inc. announced that Dr. Dongliang Chang ceases to serve as a member of the audit committee of the board of directors of the Company, effective immediately to ensure audit committee independence. Dr. Chang will continue to serve as the Chairman of Board of Directors.Is New 90 Day High Low • Dec 28New 90-day low: US$0.85The company is down 25% from its price of US$1.13 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 3.0% over the same period.お知らせ • Dec 03Molecular Data Inc. Announces Management ChangesMolecular Data Inc. announced that the Company has appointed Mr. Steven Foo as the new chief financial officer, effective December 1, 2020. Mr. Zhaohong Li has tendered his resignation as chief financial officer, for personal reasons. Mr. Foo brings over 24 years of investment, financing experience as well as financial management and restructuring work experience in Asia. Previously, Mr. Foo served as a member of the board of directors and chief financial officer of SOS Health Rescue Services. Prior to that, Mr. Foo served as a member of the board of directors and chief financial officer of Hebron Technology. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in securities laws and regulations compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets.Is New 90 Day High Low • Dec 02New 90-day low: US$1.04The company is down 11% from its price of US$1.17 on 03 September 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is down 4.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day low: US$1.09The company is down 62% from its price of US$2.87 on 17 July 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.お知らせ • Sep 29Li Li to Step Down as Vice President of Molecular Data Inc., Effective September 29, 2020Molecular Data Inc. announced that Mr. Li Li, co-founder and vice president of the Company, will step down from his current position for personal reasons, effective September 29, 2020, and will serve as the vice president of the strategy advisory committee of the Company.Is New 90 Day High Low • Sep 24New 90-day low: US$1.11The company is down 42% from its price of US$1.91 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.収支内訳Molecular Data の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MKDT.Y 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費30 Jun 214,619-2562431931 Mar 216,108-2922652731 Dec 207,596-3282863530 Sep 2010,080-2772624530 Jun 2012,525-1952144931 Mar 2012,866-1942314731 Dec 1913,207-1942484530 Sep 1912,114-3003514630 Jun 1911,260-2993404331 Mar 1910,157-2773104031 Dec 189,053-2552793730 Sep 187,829-1241352431 Dec 174,202-1081211931 Dec 163,206-11411220質の高い収益: MKDT.Yが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: MKDT.Yの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MKDT.Yの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: MKDT.Yの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: MKDT.Yの過去 1 年間の収益成長がTrade Distributors業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: MKDT.Yは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YCapital-goods 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 02:27終値2026/05/14 00:00収益2021/06/30年間収益2020/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Molecular Data Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関null nullArgus Research Company
Reported Earnings • Oct 07First half 2021 earnings released: CN¥0.22 loss per shareThe company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020).
お知らせ • Oct 27Nasdaq Stock Market to Delist the American Depositary Shares of Molecular Data IncOn October 26, 2022, Nasdaq Stock Market announced that it will delist the American Depositary Shares of Molecular Data Inc. Molecular Data’s securities were suspended on September 7, 2022, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting become effective ten days after the Form 25 is filed.
Board Change • Aug 02High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 25Molecular Data Receives NASDAQ NotificationMolecular Data Inc. announced that it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that to date, it has not regained compliance with the Rule 5250(c)(1). Since the Company is already before a Hearings Panel for its failure to comply with the $1.00 minimum bid price requirement set forth in Listing Rule 5550(a)(2),pursuant to Listing Rule 5810(d)(2), rather than submit a compliance plan for Staff's review, the Company is to address the matter before the Hearings Panel.
お知らせ • May 29Molecular Data Inc. Receives NASDAQ Notification Regarding Minimum Bid RequirementsMolecular Data Inc. announced that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that its minimum closing bid price per share for its ordinary shares had fallen below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On November 29, 2021, the Company was provided with an additional 180 calendar day compliance period, or until May 23, 2022, to demonstrate compliance. On May 24, 2022, the Company received notice from Nasdaq that it has not regained compliance with Listing Rule 5550(a)(2) and that its American Depository Shares ("ADS") would be delisted from the Capital Markets and a Form 25- NSE filed with the Securities and Exchange Commission (the "SEC") to remove the Company's securities from listing and registration on The Nasdaq Stock Market unless the Company requests a hearing for an appeal. On May 26, 2022, the Company submitted a hearing request to a Hearings Panel (the "Panel") for an appeal pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The hearing request will stay the suspension and delisting action pending the issuance of a written Panel decision.
お知らせ • May 21Molecular Data Announces Receipt of Nasdaq Non-Compliance LetterOn May 20, 2022, Molecular Data Inc. announced that on May 17, 2022, it received a Delinquency Compliance Plan Alert Letter (the "Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), because it has not timely filed its annual report on Form 20-F for the period ended December 31, 2021. In the Letter, Nasdaq stated that the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Company's Form 20-F's filing due date, or until November 14, 2022, to regain compliance.
お知らせ • May 03Molecular Data Inc. announced delayed 20-F filingOn 05/02/2022, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Board Change • Apr 27High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 08Molecular Data Inc. Adopts Blockchain to Enhance its PlatformMolecular Data Inc. has upgraded its platform using Blockchain for its current chemical business. With properties of Blockchain including traceability and transparency, such an adoption can be applied in numerous processes from the front to back end in the current business to improve credibility. Also, the transactions efficiency and safety will be enhanced.
Reported Earnings • Oct 07First half 2021 earnings released: CN¥0.22 loss per shareThe company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020).
お知らせ • Sep 24Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million.Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 23,390,000 Price\Range: $0.38 Discount Per Security: $0.0304 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 16,083,684 Price\Range: $0.3799 Discount Per Security: $0.030392 Transaction Features: Registered Direct Offering
お知らせ • Jul 15Molecular Data Inc. announced that it expects to receive $1.9 million in funding from Yorkville Advisors Global LPMolecular Data Inc. announced that it has entered into a securities purchase agreement with returning investor, YA II PN, Ltd., a fund managed by Yorkville Advisors Global LP for a private placement of convertible debentures for gross proceeds of $1,900,000 on July 14, 2021. The convertible debentures bear interest of 5% per year. The securities are issued at a discount of 5%. The investor shall be entitled to convert any portion of the outstanding and unpaid conversion amount into fully paid and nonassessable ordinary Shares. The debenture will mature on July 14, 2022 unless earlier converted or redeemed. Upon conversion, the company will issue American depositary shares to the investor. The initial conversion price shall be the lower of $1.30 per share, or 88% of a reference price benchmarked against trading price of the company's shares. Each American depositary share represents three class A ordinary shares of the company.
お知らせ • May 04Molecular Data Inc. announced delayed 20-F filingOn 05/03/2021, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Apr 10Molecular Data Inc. announced that it has received $7.5 million in fundingMolecular Data Inc. (NasdaqCM:MKD) announced that it has raised up to $7.5 million in a round of funding from accredited investor on April 9, 2021.
お知らせ • Mar 11Molecular Data Inc. Enters Supply Framework Agreement with Anhui Gujing Distillery Co., LtdMolecular Data Inc. announced that it has entered into a supply framework agreement with Anhui Gujing Distillery Co. Ltd. ("Gujing"), one of the most important core enterprises in China's liquor market, as part of its efforts to expand presence in the food and beverage industry. Under the agreement, Molecular Data will become a key supplier for Gujing and its affiliated companies, including Anhui Runan Xinke Testing Technology Co. Ltd.("Runan Xinke") and Anhui Ruisi Weier Technology Co. Ltd. ("Ruisi Weier"), in the fields of chemical reagents, biological reagents, laboratory consumables, as well as related instruments and equipment. Molecular Data will source nearly 2 million stock-keeping units (SKUs) that Gujing requires from its 21 well-known domestic and foreign laboratory brands and suppliers. Molecular Data'sMKD Lab Supplies Mall is a data-driven one-stop laboratory supplies e-commerce service platform, which covers all categories of chemical reagents, biological reagents, laboratory consumables, and equipment. The mall serves scientific research institutions, hospitals, university laboratories, third-party testing units and production plants, providing procurement services that include all categories of reagents and intermediates. With a history of more than 1,800 years, Gujing Gongjiu is one of the eight most prestigious liquor brands in China, and has won the gold medal in the national spirits appraisal four times consecutively. Gujing's research capabilities in liquor are also industry leading. In accordance with the national standards of top laboratories, Gujing has established research and development centers, national post-doctoral research workstations, academic workstations, national food enterprise quality and safety testing technology demonstration centers and other scientific research platforms. Both affiliates of Gujing, Runan Xinke is a state-owned third-party testing institution that provides one-stop testing services from inspection to testing and technical services with various national certification; while Ruisi Weier has been striving for technology development related to biological fermentation engineering. The collaboration with Gujing is another milestone for Molecular Datato propel digitalization of the traditional industries and empower intelligent manufacturing in China. Molecular Data will continue to optimize supply chain services and upgrade the digital products, helping enterprises both from China and abroad to reduce costs and increase efficiency to spur the development of the industry.
Is New 90 Day High Low • Feb 13New 90-day high: US$1.87The company is up 68% from its price of US$1.11 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 10.0% over the same period.
分析記事 • Jan 16What Percentage Of Molecular Data Inc. (NASDAQ:MKD) Shares Do Insiders Own?The big shareholder groups in Molecular Data Inc. ( NASDAQ:MKD ) have power over the company. Insiders often own a...
Is New 90 Day High Low • Jan 16New 90-day low: US$0.80The company is down 28% from its price of US$1.12 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is flat over the same period.
お知らせ • Dec 30Molecular Data Inc. Announces Cessation of Dongliang Chang as Member of the Audit Committee of the Board of DirectorsMolecular Data Inc. announced that Dr. Dongliang Chang ceases to serve as a member of the audit committee of the board of directors of the Company, effective immediately to ensure audit committee independence. Dr. Chang will continue to serve as the Chairman of Board of Directors.
Is New 90 Day High Low • Dec 28New 90-day low: US$0.85The company is down 25% from its price of US$1.13 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 3.0% over the same period.
お知らせ • Dec 03Molecular Data Inc. Announces Management ChangesMolecular Data Inc. announced that the Company has appointed Mr. Steven Foo as the new chief financial officer, effective December 1, 2020. Mr. Zhaohong Li has tendered his resignation as chief financial officer, for personal reasons. Mr. Foo brings over 24 years of investment, financing experience as well as financial management and restructuring work experience in Asia. Previously, Mr. Foo served as a member of the board of directors and chief financial officer of SOS Health Rescue Services. Prior to that, Mr. Foo served as a member of the board of directors and chief financial officer of Hebron Technology. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in securities laws and regulations compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets.
Is New 90 Day High Low • Dec 02New 90-day low: US$1.04The company is down 11% from its price of US$1.17 on 03 September 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day low: US$1.09The company is down 62% from its price of US$2.87 on 17 July 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.
お知らせ • Sep 29Li Li to Step Down as Vice President of Molecular Data Inc., Effective September 29, 2020Molecular Data Inc. announced that Mr. Li Li, co-founder and vice president of the Company, will step down from his current position for personal reasons, effective September 29, 2020, and will serve as the vice president of the strategy advisory committee of the Company.
Is New 90 Day High Low • Sep 24New 90-day low: US$1.11The company is down 42% from its price of US$1.91 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.